Controlling Hospital-Acquired Infection due to Carbapenem-Resistant Enterobacteriaceae (CRE)

  • Mitchell J. Schwaber
  • Yehuda Carmeli
  • Stephan Harbarth
Chapter

Abstract

CRE impede effective therapy of patients with Gram-negative infections. They affect patients with poor functional status, prolonged hospital stay and multiple exposures to different antibiotic agents. Detecting carbapenemase-mediated carbapenem resistance is a challenge for many microbiology laboratories using automated susceptibility testing systems. To prevent nosocomial and community transmission of CRE, we recommend strict infection control measures—including contact isolation, cohorting of carriers, and dedicated staffing—alongside active surveillance of patients at risk for carriage. Little is known regarding the added value of antibiotic stewardship interventions to control epidemic or endemic transmission of CRE.

Keywords

Antibiotic resistance Acinetobacter Pseudomonas KPC Metallo beta-lactamase OXA 

References

  1. Baraniak A, Izdebski R, Herda M, et al. Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. Antimicrob Agents Chemother 2009;53:4565-7PubMedCrossRefGoogle Scholar
  2. Ben-David D, Masarwa S, Navon-Venezia S, et al. Carbapenem-resistant Klebsiella pneumoniae in post-acute-care facilities in Israel. Infect Control Hosp Epidemiol 2011;32 (in press)Google Scholar
  3. Bilavsky E, Schwaber MJ and Carmeli Y. How to stem the tide of carbapenemase-producing enterobacteriaceae? proactive versus reactive strategies. Curr Opin Infect Dis 2010;23:327-31Google Scholar
  4. Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009;30:972-6PubMedCrossRefGoogle Scholar
  5. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165:1430-5PubMedCrossRefGoogle Scholar
  6. Bratu S, Brooks S, Burney S, et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 2007;44:972-5PubMedCrossRefGoogle Scholar
  7. Carmeli Y, Akova M, Cornaglia G, et al. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect 2010;16:102-11PubMedCrossRefGoogle Scholar
  8. Carrer A, Poirel L, Eraksoy H, Cagatay AA, Badur S and Nordmann P. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents Chemother 2008;52:2950-4PubMedCrossRefGoogle Scholar
  9. Curiao T, Morosini MI, Ruiz-Garbajosa P, et al. Emergence of bla KPC-3-Tn4401a associated with a pKPN3/4-like plasmid within ST384 and ST388 Klebsiella pneumoniae clones in Spain. J Antimicrob Chemother 2010;65:1608-14Google Scholar
  10. Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Huang TD and Nordmann P. Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. Antimicrob Agents Chemother 2008;52:3463-4PubMedCrossRefGoogle Scholar
  11. Cuzon G, Naas T, Lesenne A, Benhamou M and Nordmann P. Plasmid-mediated carbapenem-hydrolysing OXA-48 beta-lactamase in Klebsiella pneumoniae from Tunisia. Int J Antimicrob Agents 2010;36:91-3PubMedCrossRefGoogle Scholar
  12. Daikos GL, Karabinis A, Paramythiotou E, et al. VIM-1-producing Klebsiella pneumoniae bloodstream infections: analysis of 28 cases. Int J Antimicrob Agents 2007;29:471-3PubMedCrossRefGoogle Scholar
  13. Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009;53:1868-73PubMedCrossRefGoogle Scholar
  14. Davey P, Brown E, Fenelon L, et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis 2006;12:211-6PubMedCrossRefGoogle Scholar
  15. Elemam A, Rahimian J and Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 2009;49:271-4PubMedCrossRefGoogle Scholar
  16. Endimiani A, Depasquale JM, Forero S, et al. Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother 2009;64:1102-10PubMedCrossRefGoogle Scholar
  17. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007;60:1124-30PubMedCrossRefGoogle Scholar
  18. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M and Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 2009;30:1180-5PubMedCrossRefGoogle Scholar
  19. Giakkoupi P, Xanthaki A, Kanelopoulou M, et al. VIM-1 Metallo-beta-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol 2003;41:3893-6PubMedCrossRefGoogle Scholar
  20. Giakoupi P, Maltezou H, Polemis M, Pappa O, Saroglou G and Vatopoulos A. KPC-2-producing Klebsiella pneumoniae infections in Greek hospitals are mainly due to a hyperepidemic clone. Euro Surveill 2009;14Google Scholar
  21. Giani T, D’Andrea MM, Pecile P, et al. Emergence in Italy of Klebsiella pneumoniae sequence type 258 producing KPC-3 Carbapenemase. J Clin Microbiol 2009;47:3793-4PubMedCrossRefGoogle Scholar
  22. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009;48:1724-8PubMedCrossRefGoogle Scholar
  23. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996-1011PubMedCrossRefGoogle Scholar
  24. Ikonomidis A, Tokatlidou D, Kristo I, et al. Outbreaks in distinct regions due to a single Klebsiella pneumoniae clone carrying a bla VIM-1 metallo-{beta}-lactamase gene. J Clin Microbiol 2005;43:5344-7PubMedCrossRefGoogle Scholar
  25. Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009;53:3365-70PubMedCrossRefGoogle Scholar
  26. Kochar S, Sheard T, Sharma R, et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2009;30:447-52PubMedCrossRefGoogle Scholar
  27. Kwak YG, Choi SH, Choo EJ, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005;11:165-9PubMedCrossRefGoogle Scholar
  28. Leavitt A, Carmeli Y, Chmelnitsky I, Goren MG, Ofek I and Navon-Venezia S. Molecular Epidemiology, Sequence Types, and Plasmid Analyses of KPC-Producing Klebsiella pneumoniae Strains in Israel. Antimicrob Agents Chemother 2010;54:3002-6Google Scholar
  29. Lee K, Yong D, Choi YS, et al. Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 beta-lactamases co-mediated by porin loss. Int J Antimicrob Agents 2007;29:201-6PubMedCrossRefGoogle Scholar
  30. Lopez JA, Correa A, Navon-Venezia S, et al. Intercontinental spread from Israel to Colombia of a KPC-3-producing Klebsiella pneumoniae strain. Clin Microbiol Infect 2011;17:52-6Google Scholar
  31. Maltezou HC, Giakkoupi P, Maragos A, et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect 2009;58:213-9PubMedCrossRefGoogle Scholar
  32. Marchaim D, Navon-Venezia S, Schwaber MJ and Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008;52:1413-8PubMedCrossRefGoogle Scholar
  33. Matar GM, Dandache I, Carrer A, et al. Spread of OXA-48-mediated resistance to carbapenems in Lebanese Klebsiella pneumoniae and Escherichia coli that produce extended spectrum beta-lactamase. Ann Trop Med Parasitol 2010;104:271-4PubMedCrossRefGoogle Scholar
  34. Meyer E, Schwab F, Schroeren-Boersch B and Gastmeier P. Dramatic increase of third-generation cephalosporin resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001-2008. Crit Care 2010;14:R113PubMedCrossRefGoogle Scholar
  35. Munoz-Price LS, Hayden MK, Lolans K, et al. Successful control of an outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol 2010;31:341-7PubMedCrossRefGoogle Scholar
  36. Naas T, Nordmann P, Vedel G and Poyart C. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005;49:4423-4PubMedCrossRefGoogle Scholar
  37. Navon-Venezia S, Leavitt A, Schwaber MJ, et al. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother 2009;53:818-20PubMedCrossRefGoogle Scholar
  38. Osterblad M, Kirveskari J, Koskela S, et al. First isolations of KPC-2-carrying ST258 Klebsiella pneumoniae strains in Finland, June and August 2009. Euro Surveill 2009;14Google Scholar
  39. Pakyz AL, MacDougall C, Oinonen M and Polk RE. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med 2008;168:2254-60PubMedCrossRefGoogle Scholar
  40. Patel G, Huprikar S, Factor SH, Jenkins SG and Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-106PubMedCrossRefGoogle Scholar
  41. Peleg AY, Franklin C, Bell JM and Spelman DW. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005;41:1549-56PubMedCrossRefGoogle Scholar
  42. Perez F, Endimiani A, Ray AJ, et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother 2010;65:1807-18Google Scholar
  43. Pitlik SD. Oscar the cat, carbapenem-resistant Klebsiella pneumoniae, and attributable mortality. Infect Control Hosp Epidemiol 2009;30:500-1PubMedCrossRefGoogle Scholar
  44. Pournaras S, Protonotariou E, Voulgari E, et al. Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J Antimicrob Chemother 2009;64:348-52PubMedCrossRefGoogle Scholar
  45. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007;20:440-58, table of contentsPubMedCrossRefGoogle Scholar
  46. Samuelsen O, Naseer U, Tofteland S, et al. Emergence of clonally related Klebsiella pneumoniae isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden. J Antimicrob Chemother 2009;63:654-8PubMedCrossRefGoogle Scholar
  47. Schwaber MJ, Lev B, Israeli A, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011;52:848-55Google Scholar
  48. Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. Jama 2008;300:2911-3PubMedCrossRefGoogle Scholar
  49. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A and Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52:1028-33PubMedCrossRefGoogle Scholar
  50. Song W, Suh B, Choi JY, et al. In vivo selection of carbapenem-resistant Klebsiella pneumoniae by OmpK36 loss during meropenem treatment. Diagn Microbiol Infect Dis 2009;65:447-9PubMedCrossRefGoogle Scholar
  51. Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010;50:364-73PubMedCrossRefGoogle Scholar
  52. Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 2006;12:1209-13PubMedCrossRefGoogle Scholar
  53. Wei ZQ, Du XX, Yu YS, Shen P, Chen YG and Li LJ. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrob Agents Chemother 2007;51:763-5PubMedCrossRefGoogle Scholar
  54. Wendt C, Schutt S, Dalpke AH, et al. First outbreak of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in Germany. Eur J Clin Microbiol Infect Dis 2010;29:563-70PubMedCrossRefGoogle Scholar
  55. Wertheim HF, Vos MC, Boelens HA, et al. Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect 2004;56:321-5PubMedCrossRefGoogle Scholar
  56. Woodford N, Tierno PM, Jr., Young K, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 2004;48:4793-9PubMedCrossRefGoogle Scholar
  57. Woodford N, Zhang J, Warner M, et al. Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom. J Antimicrob Chemother 2008;62:1261-4PubMedCrossRefGoogle Scholar
  58. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009;53:5046-54PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Mitchell J. Schwaber
    • 1
  • Yehuda Carmeli
    • 1
    • 2
  • Stephan Harbarth
    • 3
  1. 1.National Center for Infection ControlIsrael Ministry of HealthTel AvivIsrael
  2. 2.Division of Epidemiology and Preventive MedicineTel Aviv Sourasky Medical CenterTel AvivIsrael
  3. 3.Infection Control ProgramGeneva University Hospitals & Medical SchoolGeneva 14Switzerland

Personalised recommendations